DDInter1938 DDInter1678
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Vincristine {u} (Compound) upregulates {v} (Gene) WIF1
WIF1 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Vincristine {u} (Compound) downregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Vincristine {u} (Compound) downregulates {v} (Gene) IMP3
IMP3 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Vincristine {u} (Compound) binds {v} (Gene) TUBA4A
TUBA4A {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Vincristine {u} (Compound) upregulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Vincristine {u} (Compound) causes {v} (Side Effect) Aspartate aminotransferase increased
Aspartate aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Vincristine {u} (Compound) resembles {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Vincristine (Compound) upregulates WIF1 (Gene) and WIF1 (Gene) is upregulated by Sirolimus (Compound)
Vincristine (Compound) downregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Sirolimus (Compound)
Vincristine (Compound) downregulates IMP3 (Gene) and IMP3 (Gene) is downregulated by Sirolimus (Compound)
Vincristine (Compound) binds TUBA4A (Gene) and TUBA4A (Gene) is downregulated by Sirolimus (Compound)
Vincristine (Compound) upregulates TP53BP2 (Gene) and TP53BP2 (Gene) is downregulated by Sirolimus (Compound)
Vincristine (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Vincristine (Compound) resembles Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)